TNSN08505A1 - Compositions pharmaceutiques stabilisees comprenant de la fesoterodine - Google Patents

Compositions pharmaceutiques stabilisees comprenant de la fesoterodine

Info

Publication number
TNSN08505A1
TNSN08505A1 TNP2008000505A TNSN08505A TNSN08505A1 TN SN08505 A1 TNSN08505 A1 TN SN08505A1 TN P2008000505 A TNP2008000505 A TN P2008000505A TN SN08505 A TNSN08505 A TN SN08505A TN SN08505 A1 TNSN08505 A1 TN SN08505A1
Authority
TN
Tunisia
Prior art keywords
fesoterodine
pharmaceutical compositions
stabilized pharmaceutical
stabilized
isomalt
Prior art date
Application number
TNP2008000505A
Other languages
English (en)
Inventor
Hans-Jurgen Mika
Michael Komenda
Hans Lindner
Fatima Bicane
Kerstin Paulus
Meike Irngartinger
Christoph Arth
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN08505(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of TNSN08505A1 publication Critical patent/TNSN08505A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente demande concerne une composition pharmaceutique comprenant de la fésotérodine ou un de ses sels ou produits de solvatation pharmaceutiquement acceptables et un stabilisant choisi dans le groupe consistant en le xylitol, le sorbitol, le polydextrose, l'isomalt et le dextrose.
TNP2008000505A 2006-06-09 2008-12-05 Compositions pharmaceutiques stabilisees comprenant de la fesoterodine TNSN08505A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06011941 2006-06-09
EP06011943 2006-06-09
EP06011942 2006-06-09
PCT/EP2007/055582 WO2007141298A1 (fr) 2006-06-09 2007-06-06 Compositions pharmaceutiques stabilisées contenant de la fésotérodine

Publications (1)

Publication Number Publication Date
TNSN08505A1 true TNSN08505A1 (fr) 2010-04-14

Family

ID=38521333

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000505A TNSN08505A1 (fr) 2006-06-09 2008-12-05 Compositions pharmaceutiques stabilisees comprenant de la fesoterodine

Country Status (38)

Country Link
EP (1) EP2029134B1 (fr)
JP (2) JP4743321B2 (fr)
KR (1) KR101316773B1 (fr)
CN (1) CN101466371B (fr)
AP (1) AP2416A (fr)
AR (1) AR061289A1 (fr)
AT (1) ATE517619T1 (fr)
AU (1) AU2007255408B2 (fr)
BR (1) BRPI0712865B1 (fr)
CA (1) CA2652712C (fr)
CR (1) CR10494A (fr)
CU (1) CU23850B1 (fr)
CY (1) CY1111934T1 (fr)
DK (1) DK2029134T3 (fr)
EA (1) EA015909B9 (fr)
EC (1) ECSP089010A (fr)
ES (1) ES2370943T3 (fr)
GT (1) GT200800276A (fr)
HK (1) HK1128626A1 (fr)
HR (1) HRP20110776T1 (fr)
IL (2) IL195732A (fr)
MA (1) MA30504B1 (fr)
MX (1) MX2008015736A (fr)
MY (1) MY146574A (fr)
NI (1) NI200800318A (fr)
NL (1) NL2000690C2 (fr)
NO (1) NO341980B1 (fr)
NZ (1) NZ572616A (fr)
PE (2) PE20080331A1 (fr)
PL (1) PL2029134T3 (fr)
PT (1) PT2029134E (fr)
RS (1) RS51973B (fr)
SI (1) SI2029134T1 (fr)
TN (1) TNSN08505A1 (fr)
TW (2) TWI397409B (fr)
UY (1) UY30394A1 (fr)
WO (1) WO2007141298A1 (fr)
ZA (1) ZA200806411B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294047A2 (fr) * 2008-04-04 2011-03-16 Actavis Group PTC EHF Nouveau sel de type mandélate de fésotérodine
IT1392082B1 (it) 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
CA2761602C (fr) 2009-05-11 2015-07-07 Ratiopharm Gmbh Desfesoterodine sous forme de sel d'acide tartrique
EP2316432A1 (fr) 2009-10-30 2011-05-04 ratiopharm GmbH Composition contenant de la fésotérodine et des fibres alimentaires
WO2011117884A1 (fr) * 2010-03-22 2011-09-29 Cadila Healthcare Limited Compositions pharmaceutiques stables comprenant de la fésotérodine
TWI520732B (zh) 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
EP2508175A1 (fr) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Composition pharmaceutique contenant de la fésotérodine ou un sel ou un solvate de celle-ci
EP2508173A1 (fr) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Composition pharmaceutique stable comportant de la fésotérodine
US20140199401A1 (en) * 2011-07-04 2014-07-17 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
WO2013046194A2 (fr) * 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited Nouveaux marqueurs de référence pour le fumarate de fésotérodine
ES2674811T3 (es) * 2012-07-02 2018-07-04 Hetero Research Foundation Composiciones estables de fesoterodina
DK2914255T3 (da) 2012-11-02 2021-10-25 Murray & Poole Entpr Ltd Behandling eller forebyggelse af kardiovaskulære hændelser via administration af colchicin
AU2014255434B2 (en) 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (fr) 2017-07-12 2019-01-17 Rontis Hellas S.A. Composition pharmaceutique à libération prolongée contenant de la fésotérodine et procédé de préparation de cette dernière
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
WO2019132832A1 (fr) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions de comprimés de fumarate de fésotérodine
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
EP3784217A1 (fr) 2018-04-26 2021-03-03 Rontis Hellas S.A. Composition pharmaceutique à libération prolongée contenant de la fésotérodine et son procédé de préparation
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2023145486A1 (fr) * 2022-01-28 2023-08-03 沢井製薬株式会社 Méthode de production d'une formulation contenant du fumarate de fésotérodine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044604A1 (fr) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Compositions pharmaceutiques contenant un [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate sodique, inhibiteur des phospholipases
EP0957073A1 (fr) 1998-05-12 1999-11-17 Schwarz Pharma Ag Dérivés de 3,3-diphénylpropylamines
DE29923134U1 (de) 1999-11-16 2000-06-29 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Also Published As

Publication number Publication date
NO341980B1 (no) 2018-03-05
JP4781489B2 (ja) 2011-09-28
RS51973B (en) 2012-02-29
WO2007141298A1 (fr) 2007-12-13
CU20080235A7 (es) 2011-04-26
NZ572616A (en) 2010-11-26
ES2370943T3 (es) 2011-12-23
MX2008015736A (es) 2009-01-09
ECSP089010A (es) 2009-01-30
CY1111934T1 (el) 2015-11-04
EA015909B9 (ru) 2012-03-30
EA200802444A1 (ru) 2009-06-30
TWI397409B (zh) 2013-06-01
AU2007255408A1 (en) 2007-12-13
AP2416A (en) 2012-06-01
AP2008004673A0 (en) 2008-12-31
EP2029134A1 (fr) 2009-03-04
BRPI0712865A2 (pt) 2012-12-18
MY146574A (en) 2012-08-30
TWI520735B (zh) 2016-02-11
CN101466371A (zh) 2009-06-24
PL2029134T3 (pl) 2011-12-30
NL2000690C2 (nl) 2008-04-01
MA30504B1 (fr) 2009-06-01
IL195732A (en) 2013-09-30
NL2000690A1 (nl) 2007-12-11
GT200800276A (es) 2009-06-18
UY30394A1 (es) 2007-11-30
HRP20110776T1 (hr) 2011-11-30
JP2011140498A (ja) 2011-07-21
PE20080331A1 (es) 2008-06-19
PE20120476A1 (es) 2012-04-20
NI200800318A (es) 2011-01-12
TW200814992A (en) 2008-04-01
JP4743321B2 (ja) 2011-08-10
IL220800A (en) 2015-03-31
NO20090141L (no) 2009-01-09
KR101316773B1 (ko) 2013-10-15
SI2029134T1 (sl) 2012-01-31
JP2009539802A (ja) 2009-11-19
EA015909B1 (ru) 2011-12-30
TW201336491A (zh) 2013-09-16
KR20090026135A (ko) 2009-03-11
DK2029134T3 (da) 2011-10-17
AR061289A1 (es) 2008-08-20
CR10494A (es) 2009-01-19
EP2029134B1 (fr) 2011-07-27
CA2652712C (fr) 2014-04-01
BRPI0712865B1 (pt) 2021-08-17
AU2007255408B2 (en) 2013-03-14
CA2652712A1 (fr) 2007-12-13
PT2029134E (pt) 2011-11-02
IL195732A0 (en) 2009-09-01
ZA200806411B (en) 2009-05-27
HK1128626A1 (en) 2009-11-06
CU23850B1 (es) 2012-10-15
CN101466371B (zh) 2011-10-05
ATE517619T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
TNSN08505A1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
MA29909B1 (fr) Derives de pyridazine
WO2007061661A4 (fr) Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
NO20082538L (no) Stabiliserte lantankarbonatsammensetninger
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
WO2008042688A3 (fr) Inhibiteurs de co-transporteur 2 de sodium glucose et procédés d'utilisation de ceux-ci
BRPI0714055B8 (pt) compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo
ATE409048T1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
WO2010063476A3 (fr) Formes posologiques solides de bendamustine
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
WO2012048129A3 (fr) Inhibiteurs de kinase de type polo
WO2010030704A3 (fr) Analogues d’aminoglycosides antibactériens
WO2005075471A3 (fr) Composes thiazole utilises en tant qu'inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
WO2008133330A1 (fr) Préparation solide stable comprenant un dérivé de 4,5-époxymorphinane
WO2008014361A3 (fr) Dérivés cycliques en tant que modulateurs de l'activité des récepteurs de chimiokines
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
SE0303480D0 (sv) Benzofuranes
ATE418540T1 (de) Galloylpeptide
WO2007121545A8 (fr) Compositions contenant des s-nitrosothiols et utilisation de ces compositions
WO2007117563A3 (fr) COMPOSÉS DE LA 1α-HYDROXY-2-(3'-HYDROXYPROPYLIDÈNE)-19-NOR-VITAMINE D ET PROCÉDÉS DE PRODUCTION ET DE TRAITEMENT ASSOCIÉS